Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for coronary microvascular dysfunction
ACTRN12625000282482Phase 4Recruiting
- Sponsor
- Monash University
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Coronary Small Vessel Disease (CMD) comparing Empagliflozin plus standard of care with Standard of care (2 arms). Primary endpoint: Coronary microvascular resistance. Started Mar 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
Coronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on ACTRN12625000282482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000282482.